Nektar Therapeutics
NASDAQ:NKTRBiotechnology
Healthcare
$32.54 -2.04%
-$1.24 today
- Market cap
- $933.51M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
52W Low $8.27High $109.00
Volume 0.86M
Average 1.00M
Income Statement
Follow revenue through to earnings.
Revenue
$55.23M
FY 2025 · Annual
-43.9% YoYOperating Income
-$130.77M
FY 2025 · Annual
Net Income
-$164.08M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M |
| Cost of Revenue | 24.9M | 21.64M | 36.64M | 30.69M | 0 |
| Gross Profit | 77.01M | 70.42M | 53.48M | 67.74M | 55.23M |
| Gross Margin | 75.6% | 76.5% | 59.3% | 68.8% | 100.0% |
| Research & Development | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M |
| Selling, General & Admin | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M |
| Operating Expenses | 523.11M | 310.66M | 190.9M | 172.94M | 186M |
| Depreciation & Amortization | 14.15M | 12.2M | 7.82M | 4.39M | 1.03M |
| EBITDA | (461.82M) | (323.87M) | (243.11M) | (86.7M) | (137M) |
| EBITDA Margin | -453.2% | -351.8% | -269.8% | -88.1% | -248.1% |
| Operating Income | (446.1M) | (240.24M) | (137.43M) | (105.2M) | (130.77M) |
| Operating Margin | -437.8% | -261.0% | -152.5% | -106.9% | -236.8% |
| Interest Income | 2.73M | 6.78M | 19.01M | 14.5M | 10.44M |
| Interest Expense | 47.31M | 28.91M | 25.33M | 28.11M | 26.18M |
| Other Income / Expenses | (77.18M) | (124.75M) | (138.83M) | (14M) | (33.44M) |
| Income Before Tax | (523.28M) | (364.98M) | (276.26M) | (119.2M) | (164.21M) |
| Pre-Tax Margin | -513.5% | -396.5% | -306.5% | -121.1% | -297.3% |
| Income Tax Expense | 557K | 3.22M | (200K) | (239K) | (138K) |
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Net Margin | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% |
| EPS (Basic) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| EPS (Diluted) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| 12.22M | 12.48M | 12.67M | 13.71M | 16.87M | |
| 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
NKTR Earnings Waterfall · TTM
NASDAQ:NKTR · Revenue to Net Income
Key Ratios
EPS$-6.70
Gross Margin99.2%
Net Margin-320.3%
P/E Ratio-9.4
P/S Ratio124.7
Analysis
$54.6M of revenue converted into -$157.1M of net income for the selected period. Gross margin is 99.2% and net margin is -320.3%, showing how much revenue survives after costs and taxes. EPS is $-6.70, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| S-8 | S-8 filing | Oct 20, 2026 |
How much revenue does NKTR generate?
Nektar Therapeutics (NKTR) reported $55.23M of revenue in fiscal 2025.
Is NKTR profitable?
Nektar Therapeutics (NKTR) reported -$164.08M of net income, with a net margin of -297.1%.
Continue the stock analysis
Jump to another research area for this company.